An innovative research effort has found that providing pluripotent cells to developing infants suffering from spina bifida while undergoing fetal surgery may represent a "major milestone" in addressing congenital conditions.
Study Parameters and Security
The US-based trial focused on six developing infants with myelomeningocele. Surgeons applied placenta-derived mesenchymal stem cells directly onto the baby's spinal cord as part of the surgical correction.
Importantly, the stem cell application was found to be safe. Researchers confirmed that the therapy did not induce cancerous growths, disrupt the healing process, or impede the resolution of co-occurring hindbrain herniation.
Encouraging Results
Imaging conducted after delivery confirmed a successful correction of Chiari malformation in every participant. This favorable anatomical change is a key indicator for enhanced physical outcomes.
"If it makes a greater number of infants able to walk who wouldn't have, it may emerge as the conventional approach," noted the study director. "The outcomes appear super exciting and create a pathway toward lots of potential new treatments."
Broader Impact and Encouragement
Experts not involved in the trial proposed that further confirmation of these noted improvements could herald a "new era" in fetal surgery. The potential to improve nerve function impairment seen in utero is considered a transformative goal.
Particularly welcome would be advancements for bladder and bowel function, which are typical difficulties for those diagnosed with this condition.
The Path Forward
Despite this being a first-in-human effort involved a limited number of patients, its safety demonstration and positive signals offer a robust platform for broader investigative efforts. The combination of regenerative medicine with current in-utero repair procedures offers substantial hope for changing life trajectories for future generations with spina bifida.